Lonza to acquire InterHealth Nutraceuticals

17 Aug 2016

Lonza is to acquire InterHealth Nutraceuticals for up to $300 million. InterHealth offers more than 15 branded ingredients, including its joint health ingredient, UC-II, and it is said to it complement Lonza’s existing nutritional portfolio.

Lonza to acquire InterHealth Nutraceuticals

Lonza is to acquire InterHealth Nutraceuticals for up to $300 million.

“With this acquisition Lonza is taking a further step along our strategic path as a high-value supplier to the healthcare continuum,” said Richard Ridinger, Lonza’s Chief Executive Officer. “Lonza will leverage the successful product portfolio of InterHealth on a global level and in turn will be able to benefit from InterHealth’s proven management and branding capabilities to promote Lonza’s existing product portfolio. We see significant positive synergies from this combination.”

InterHealth offers more than 15 branded ingredients, including its joint health ingredient, UC-II, and it is said to it complement Lonza’s existing nutritional portfolio in the area of sports nutrition, weight management, immune health and pet health. The acquisition will also expand Lonza’s offerings into new areas such as cognitive and diabetic health.